JP2017529382A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2017529382A5 JP2017529382A5 JP2017516874A JP2017516874A JP2017529382A5 JP 2017529382 A5 JP2017529382 A5 JP 2017529382A5 JP 2017516874 A JP2017516874 A JP 2017516874A JP 2017516874 A JP2017516874 A JP 2017516874A JP 2017529382 A5 JP2017529382 A5 JP 2017529382A5
- Authority
- JP
- Japan
- Prior art keywords
- pyridin
- amino
- trifluoromethyl
- pharmaceutical composition
- methyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000008194 pharmaceutical composition Substances 0.000 claims description 15
- 239000003112 inhibitor Substances 0.000 claims description 8
- 208000032612 Glial tumor Diseases 0.000 claims description 7
- 206010018338 Glioma Diseases 0.000 claims description 7
- 206010002449 angioimmunoblastic T-cell lymphoma Diseases 0.000 claims description 7
- 108700028369 Alleles Proteins 0.000 claims description 5
- 208000005243 Chondrosarcoma Diseases 0.000 claims description 4
- 208000006990 cholangiocarcinoma Diseases 0.000 claims description 4
- 201000001441 melanoma Diseases 0.000 claims description 4
- 239000006186 oral dosage form Substances 0.000 claims description 4
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims 7
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims 7
- 125000004105 2-pyridyl group Chemical group N1=C([*])C([H])=C([H])C([H])=C1[H] 0.000 claims 4
- 125000000339 4-pyridyl group Chemical group N1=C([H])C([H])=C([*])C([H])=C1[H] 0.000 claims 3
- URUBZXVIOILFLM-UHFFFAOYSA-N CC(C)(CNc1nc(Nc2ccnc(c2)C(F)(F)F)nc(n1)-c1cccc(n1)C(F)(F)F)OS(C)(=O)=O Chemical compound CC(C)(CNc1nc(Nc2ccnc(c2)C(F)(F)F)nc(n1)-c1cccc(n1)C(F)(F)F)OS(C)(=O)=O URUBZXVIOILFLM-UHFFFAOYSA-N 0.000 claims 3
- DYLUUSLLRIQKOE-UHFFFAOYSA-N enasidenib Chemical compound N=1C(C=2N=C(C=CC=2)C(F)(F)F)=NC(NCC(C)(O)C)=NC=1NC1=CC=NC(C(F)(F)F)=C1 DYLUUSLLRIQKOE-UHFFFAOYSA-N 0.000 claims 3
- 125000004317 1,3,5-triazin-2-yl group Chemical group [H]C1=NC(*)=NC([H])=N1 0.000 claims 2
- 102000012011 Isocitrate Dehydrogenase Human genes 0.000 claims 2
- 108010075869 Isocitrate Dehydrogenase Proteins 0.000 claims 2
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 claims 2
- 206010028980 Neoplasm Diseases 0.000 claims 2
- SWWHCQCMVCPLEQ-UHFFFAOYSA-N propan-2-yl methanesulfonate Chemical compound CC(C)OS(C)(=O)=O SWWHCQCMVCPLEQ-UHFFFAOYSA-N 0.000 claims 2
- -1 {[2- (trifluoromethyl) pyridin-4-yl] amino} -1,3,5-triazin-2-yl Chemical group 0.000 claims 1
- 230000035772 mutation Effects 0.000 description 13
- 101000599886 Homo sapiens Isocitrate dehydrogenase [NADP], mitochondrial Proteins 0.000 description 10
- 102100037845 Isocitrate dehydrogenase [NADP], mitochondrial Human genes 0.000 description 10
- 229940125782 compound 2 Drugs 0.000 description 7
- 238000000034 method Methods 0.000 description 7
- 229940125904 compound 1 Drugs 0.000 description 6
- 150000001875 compounds Chemical class 0.000 description 4
- 230000003902 lesion Effects 0.000 description 4
- 208000037844 advanced solid tumor Diseases 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 238000002360 preparation method Methods 0.000 description 3
- 239000002552 dosage form Substances 0.000 description 2
- 239000003937 drug carrier Substances 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- 230000005764 inhibitory process Effects 0.000 description 2
- HWXBTNAVRSUOJR-UHFFFAOYSA-N 2-hydroxyglutaric acid Chemical compound OC(=O)C(O)CCC(O)=O HWXBTNAVRSUOJR-UHFFFAOYSA-N 0.000 description 1
- KPGXRSRHYNQIFN-UHFFFAOYSA-N 2-oxoglutaric acid Chemical compound OC(=O)CCC(=O)C(O)=O KPGXRSRHYNQIFN-UHFFFAOYSA-N 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 206010042971 T-cell lymphoma Diseases 0.000 description 1
- 208000027585 T-cell non-Hodgkin lymphoma Diseases 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 239000012876 carrier material Substances 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 239000012458 free base Substances 0.000 description 1
- 230000001401 hemangioblastic effect Effects 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 238000001361 intraarterial administration Methods 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 210000001165 lymph node Anatomy 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 238000010254 subcutaneous injection Methods 0.000 description 1
- 239000007929 subcutaneous injection Substances 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201462056996P | 2014-09-29 | 2014-09-29 | |
| US62/056,996 | 2014-09-29 | ||
| PCT/US2015/052598 WO2016053850A1 (en) | 2014-09-29 | 2015-09-28 | Therapeutically active compounds and their methods of use |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020084527A Division JP2020147571A (ja) | 2014-09-29 | 2020-05-13 | 治療活性を有する化合物及びその使用方法 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2017529382A JP2017529382A (ja) | 2017-10-05 |
| JP2017529382A5 true JP2017529382A5 (enExample) | 2018-11-01 |
Family
ID=54289133
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017516874A Pending JP2017529382A (ja) | 2014-09-29 | 2015-09-28 | 治療活性を有する化合物及びその使用方法 |
| JP2020084527A Pending JP2020147571A (ja) | 2014-09-29 | 2020-05-13 | 治療活性を有する化合物及びその使用方法 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020084527A Pending JP2020147571A (ja) | 2014-09-29 | 2020-05-13 | 治療活性を有する化合物及びその使用方法 |
Country Status (8)
| Country | Link |
|---|---|
| US (3) | US9694013B2 (enExample) |
| EP (1) | EP3200800A1 (enExample) |
| JP (2) | JP2017529382A (enExample) |
| KR (1) | KR20170057411A (enExample) |
| AU (1) | AU2015324158A1 (enExample) |
| CA (1) | CA2962943A1 (enExample) |
| IL (1) | IL251246A0 (enExample) |
| WO (1) | WO2016053850A1 (enExample) |
Families Citing this family (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TWI701242B (zh) | 2013-08-02 | 2020-08-11 | 美商阿吉斯藥品股份有限公司 | 治療活性化合物及其使用方法(三) |
| CA2962943A1 (en) | 2014-09-29 | 2016-04-07 | Agios Pharmaceuticals, Inc. | Therapeutically active compounds and their methods of use |
| EP3253746A1 (en) | 2015-02-04 | 2017-12-13 | Agios Pharmaceuticals, Inc. | Therapeutically active compounds and their methods of use |
| MX365590B (es) | 2015-08-05 | 2019-06-07 | Agios Pharmaceuticals Inc | Metodos para preparar 6-(aril o heteroaril)-1,3,5-triazin-2,4-diol es y 6-(aril o heteroaril)-1,3,5-triazin-2,4-diaminas. |
| ES2862730T3 (es) | 2015-10-15 | 2021-10-07 | Celgene Corp | Combinación de un inhibidor de isocitrato deshidrogenasa 2 mutante con azacitidina y su uso para el tratamiento de la leucemia mielógena aguda |
| WO2017066599A1 (en) | 2015-10-15 | 2017-04-20 | Agios Pharmaceuticals, Inc. | Combination therapy for treating malignancies |
| MA43374A (fr) | 2015-12-04 | 2018-10-10 | Agios Pharmaceuticals Inc | Méthodes de traitement de tumeurs malignes |
| JP6930991B2 (ja) | 2016-02-26 | 2021-09-01 | セルジーン コーポレイション | 血液学的悪性腫瘍及び固形腫瘍の治療のためのｉｄｈ２阻害剤 |
| WO2018010142A1 (en) * | 2016-07-14 | 2018-01-18 | Shanghai Meton Pharmaceutical Co., Ltd | Iso-citrate dehydrogenase (idh) inhibitor |
| BR112019004356A2 (pt) | 2016-09-07 | 2019-05-28 | Celgene Corporation | composições de comprimido |
| EP3618828B1 (en) | 2017-05-05 | 2023-11-01 | Memorial Sloan Kettering Cancer Center | Methods of treatment of myeloproliferative neoplasm |
| JP7306634B2 (ja) * | 2017-10-19 | 2023-07-11 | 一般社団法人ファルマバレープロジェクト支援機構 | Ｉｄｏ／ｔｄｏ阻害剤 |
| US11312723B2 (en) * | 2017-11-29 | 2022-04-26 | The Rockefeller University | Pyranopyrazole and pyrazolopyridine immunomodulators for treatment of autoimmune diseases |
| WO2020092894A1 (en) | 2018-11-02 | 2020-05-07 | Celgene Corporation | Solid forms of 2-methyl-1-[(4-[6-(trifluoromethyl) pyridin-2-yl]-6-{[2-(trifluoromethyl)pyridin-4-yl]amino}-1,3,5-triazin-2-yl) amino]propan-2-ol |
| WO2020092915A1 (en) | 2018-11-02 | 2020-05-07 | Celgene Corporation | Solid dispersions for treatment of cancer |
| US20220017490A1 (en) | 2018-11-02 | 2022-01-20 | Celgene Corporation | Co-crystals of 2-methyl-1 -[(4-[6-(trifluoromethyl)pyridin-2-yl]-6-{[2-(trifluoromethyl) pyridin-4-yl]amino}-1,3,5-triazin-2-yl)amino]propan-2-ol, compositions and methods of use thereof |
| WO2020239759A1 (en) * | 2019-05-27 | 2020-12-03 | Sandoz Ag | Amorphous enasidenib in a stabilized form |
| WO2021097160A1 (en) | 2019-11-14 | 2021-05-20 | Celgene Corporation | Pediatric formulations for treatment of cancer |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| HUE038403T2 (hu) | 2012-01-06 | 2018-10-29 | Agios Pharmaceuticals Inc | Terápiásan alkalmazható vegyületek és alkalmazási módszereik |
| US9579324B2 (en) | 2013-07-11 | 2017-02-28 | Agios Pharmaceuticals, Inc | Therapeutically active compounds and their methods of use |
| BR112016000489A8 (pt) | 2013-07-11 | 2020-01-07 | Agios Pharmaceuticals Inc | composto, composição farmacêutica que o compreende, uso da composição e métodos para fabricar compostos |
| TWI701242B (zh) | 2013-08-02 | 2020-08-11 | 美商阿吉斯藥品股份有限公司 | 治療活性化合物及其使用方法(三) |
| CA2962943A1 (en) * | 2014-09-29 | 2016-04-07 | Agios Pharmaceuticals, Inc. | Therapeutically active compounds and their methods of use |
| EP3253746A1 (en) | 2015-02-04 | 2017-12-13 | Agios Pharmaceuticals, Inc. | Therapeutically active compounds and their methods of use |
| MX365590B (es) | 2015-08-05 | 2019-06-07 | Agios Pharmaceuticals Inc | Metodos para preparar 6-(aril o heteroaril)-1,3,5-triazin-2,4-diol es y 6-(aril o heteroaril)-1,3,5-triazin-2,4-diaminas. |
| WO2017066599A1 (en) | 2015-10-15 | 2017-04-20 | Agios Pharmaceuticals, Inc. | Combination therapy for treating malignancies |
| MA43374A (fr) | 2015-12-04 | 2018-10-10 | Agios Pharmaceuticals Inc | Méthodes de traitement de tumeurs malignes |
| JP6930991B2 (ja) | 2016-02-26 | 2021-09-01 | セルジーン コーポレイション | 血液学的悪性腫瘍及び固形腫瘍の治療のためのｉｄｈ２阻害剤 |
-
2015
- 2015-09-28 CA CA2962943A patent/CA2962943A1/en not_active Abandoned
- 2015-09-28 KR KR1020177010757A patent/KR20170057411A/ko not_active Ceased
- 2015-09-28 AU AU2015324158A patent/AU2015324158A1/en not_active Abandoned
- 2015-09-28 WO PCT/US2015/052598 patent/WO2016053850A1/en not_active Ceased
- 2015-09-28 US US14/868,283 patent/US9694013B2/en active Active
- 2015-09-28 JP JP2017516874A patent/JP2017529382A/ja active Pending
- 2015-09-28 EP EP15778158.4A patent/EP3200800A1/en not_active Withdrawn
-
2017
- 2017-03-17 IL IL251246A patent/IL251246A0/en unknown
- 2017-06-02 US US15/612,984 patent/US9889137B2/en active Active
-
2018
- 2018-01-08 US US15/864,994 patent/US10105369B2/en active Active
-
2020
- 2020-05-13 JP JP2020084527A patent/JP2020147571A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2017529382A5 (enExample) | ||
| US12011449B2 (en) | Therapeutic combinations comprising a c-RAF inhibitor | |
| Dong et al. | New biologics in psoriasis: an update on IL-23 and IL-17 inhibitors | |
| JP5579715B2 (ja) | ｃｄｋ阻害剤および抗悪性腫瘍剤を含む治療用組合せ | |
| US9161946B2 (en) | Dosing methods for treating disease | |
| JP2016540738A5 (enExample) | ||
| Norden et al. | Ibuprofen ameliorates fatigue-and depressive-like behavior in tumor-bearing mice | |
| JP2015528471A5 (enExample) | ||
| JP2014515373A5 (enExample) | ||
| JP2018534311A5 (enExample) | ||
| BR112014027010A2 (pt) | uso de laquinimod de alta dose para tratamento de esclerose múltipla | |
| JP2014525454A5 (enExample) | ||
| JP2016517401A5 (enExample) | ||
| US20190290652A1 (en) | Method for treatment of solid malignancies including advanced or metastatic solid malignancies | |
| FI3463345T3 (fi) | Farmaseuttisia yhdistelmiä | |
| JP2023515765A (ja) | Ｂｉ８５３５２０と化学療法薬の併用 | |
| KR20170098813A (ko) | 대장암 치료에 사용하기 위한 아필리모드 | |
| TW202214242A (zh) | 西奧羅尼或其衍生物在製備用於預防和/或治療非霍奇金淋巴瘤的藥物之用途 | |
| JP2011513310A5 (enExample) | ||
| KR20120023754A (ko) | Ａｖｅ８０６２ 및 소라페닙을 포함하는 항종양 조합물 | |
| JP2020500868A5 (enExample) | ||
| JP2018522049A5 (enExample) | ||
| JP2023509191A (ja) | 癌を治療するための組み合わせ療法 | |
| JP2022540198A (ja) | 組合せ | |
| WO2023281413A1 (en) | Methods and dosing regimens comprising pf-06873600 for the treatment of cancer |